[{"data":1,"prerenderedAt":241},["ShallowReactive",2],{"$f310r5jk1hmr44":3},{"schema":4,"slug":5,"series":6,"series_slug":7,"name":8,"year":9,"therapeutic_area":10,"generated_at":11,"counts":12,"top_targets":21,"top_modalities":54,"top_diseases":79,"top_companies":110,"key_results":139,"trends":225,"previous_editions":234,"comparison":154,"highlighted_classes":238},1,"wclc-2026","WCLC","wclc","World Conference on Lung Cancer 2026",2026,"Oncology","2026-11-05T22:19:09Z",{"abstracts":13,"drug_linked":14,"companies":15,"by_phase":16},1875,688,119,{"Phase 1":17,"Phase 1\u002F2":18,"Phase 2":19,"Phase 3":20},39,20,150,64,[22,26,30,34,38,42,45,47,49,51],{"name":23,"count":24,"share":25},"PDCD1",159,23,{"name":27,"count":28,"share":29},"EGFR",146,21,{"name":31,"count":32,"share":33},"CD274",76,11,{"name":35,"count":36,"share":37},"ALK",35,5,{"name":39,"count":40,"share":41},"ERBB2",29,4,{"name":43,"count":25,"share":44},"VEGFA",3,{"name":46,"count":29,"share":44},"DLL3",{"name":48,"count":29,"share":44},"MET",{"name":50,"count":18,"share":44},"CD3",{"name":52,"count":53,"share":44},"NTRK1",19,[55,59,63,67,71,73,75,77],{"name":56,"count":57,"share":58},"Small molecules",369,54,{"name":60,"count":61,"share":62},"Monoclonal antibodies",260,38,{"name":64,"count":65,"share":66},"Bispecific antibodies",68,10,{"name":68,"count":69,"share":70},"Antibody-drug conjugates",49,7,{"name":72,"count":66,"share":4},"Non-antibody therapeutic proteins",{"name":74,"count":66,"share":4},"Oligonucleotide and RNA therapeutics",{"name":76,"count":70,"share":4},"Cell therapies",{"name":78,"count":70,"share":4},"Radiopharmaceuticals",[80,84,88,92,94,97,101,104,106,108],{"name":81,"count":82,"share":83},"non-small cell lung cancer (NSCLC)",485,70,{"name":85,"count":86,"share":87},"small cell lung cancer (SCLC)",107,16,{"name":89,"count":90,"share":91},"Non-small cell lung cancer adenocarcinoma (NSCLC)",56,8,{"name":93,"count":36,"share":37},"bronchial carcinoma",{"name":95,"count":96,"share":44},"brain metastases",24,{"name":98,"count":99,"share":100},"Carcinomatous Meningitis (CM)",14,2,{"name":102,"count":103,"share":100},"pleural mesothelioma",12,{"name":105,"count":33,"share":100},"Pulmonary squamous cell carcinoma",{"name":107,"count":91,"share":4},"Non-small cell lung cancer (NS-NSCLC)",{"name":109,"count":70,"share":4},"apudoma (NET)",[111,115,118,122,125,127,129,132,134,136],{"name":112,"count":113,"share":114},"AstraZeneca",120,17,{"name":116,"count":117,"share":70},"Bristol Myers Squibb",50,{"name":119,"count":120,"share":121},"Merck",42,6,{"name":123,"count":124,"share":121},"BeiGene",40,{"name":126,"count":40,"share":41},"Genentech",{"name":128,"count":25,"share":44},"Amgen",{"name":130,"count":131,"share":44},"Pfizer",22,{"name":133,"count":114,"share":100},"Jiangsu HengRui Medicine Co., Ltd.",{"name":135,"count":87,"share":100},"Eli Lilly",{"name":137,"count":138,"share":100},"Allist Pharmaceuticals, Inc.",15,[140,149,157,163,170,177,185,191,198,204,211,218],{"title":141,"drug":142,"company":145,"phase":146,"disease":85,"finding":147,"url":148},"Tam-Peli, an Anti-B7-H3 Antibody-Drug Conjugate, Versus Topotecan in Relapsed SCLC: A Randomized, Open-Label, Phase 3 Study (TAISHAN-302)",{"name":143,"slug":144},"YL201","yl201","MediLink Therapeutics","Phase 3","Median OS was 13.3 months (95% CI: 12.1-NE) with Tam-Peli versus 9.4 months (95% CI: 7.7-10.5) with topotecan (stratified hazard ratio [HR] 0.46; 95% CI: 0.35-0.62; p \u003C0.0001).","https:\u002F\u002Fcattendee.abstractsonline.com\u002Fmeeting\u002F21487\u002FPresentation\u002F5028",{"title":150,"drug":151,"company":154,"phase":146,"disease":85,"finding":155,"url":156},"Risvutatug Rezetecan (a B7-H3-Directed ADC) Versus Topotecan in Relapsed SCLC: Primary Results of Phase 3 ARTEMIS-008",{"name":152,"slug":153},"risvutatug rezetecan","risvutatug-rezetecan",null,"Per blinded independent central review (BICR) assessment, PFS (median PFS, 7.2 mo vs. 3.0 mo; HR 0.33 [95% CI, 0.25-0.42]), ORR (58.3% vs. 12.6%), and DCR (90.4% vs. 60.2%) all favored Ris-Rez.","https:\u002F\u002Fcattendee.abstractsonline.com\u002Fmeeting\u002F21487\u002FPresentation\u002F5029",{"title":158,"drug":159,"company":126,"phase":146,"disease":81,"finding":161,"url":162},"Final Analysis of the Phase 3 IMpower030 Study: Perioperative Atezolizumab + Chemotherapy in Resectable Stage II-IIIB NSCLC",{"name":160,"slug":160},"atezolizumab","In the stage IIB-IIIB-WT population, after a median follow up of 69.3 months, median IRF-EFS was 62.8 versus 34.9 months, IRF-pCR rates were 29.6% versus 8.5%, and IRF-MPR rates were 53.6% versus 24.4% for atezolizumab plus PC versus placebo plus PC, respectively.","https:\u002F\u002Fcattendee.abstractsonline.com\u002Fmeeting\u002F21487\u002FPresentation\u002F1849",{"title":164,"drug":165,"company":167,"phase":146,"disease":81,"finding":168,"url":169},"Zipalertinib Plus Chemotherapy for 1 st Line NSCLC with EGFR Exon 20 Insertions: Results From the Phase 3 Trial (REZILIENT 3)",{"name":166,"slug":166},"zipalertinib","Taiho Pharmaceutical","At the pre-planned efficacy analysis of 122 PFS events, the combination treatment with zipalertinib led to significantly longer median PFS than chemotherapy alone (14.5 vs. 8.5 months; HR: 0.50; 95% CI 0.34-0.73; P=0.00015).","https:\u002F\u002Fcattendee.abstractsonline.com\u002Fmeeting\u002F21487\u002FPresentation\u002F5108",{"title":171,"drug":172,"company":154,"phase":146,"disease":81,"finding":175,"url":176},"First-Line Trastuzumab Deruxtecan (T-DXd) in Patients With Metastatic HER2 -Mutant NSCLC: DESTINY-Lung04 Primary Results",{"name":173,"slug":174},"trastuzumab deruxtecan","trastuzumab-deruxtecan","T-DXd demonstrated a statistically significant improvement in PFS versus pembro+chemo (median [95% CI], 14.3 [12.4, 16.5] months versus 8.3 [7.0, 9.9] months, respectively; HR [95% CI] 0.63 [0.50, 0.79], P\u003C0.0001; 6-month PFS improvement).","https:\u002F\u002Fcattendee.abstractsonline.com\u002Fmeeting\u002F21487\u002FPresentation\u002F5033",{"title":178,"drug":179,"company":182,"phase":146,"disease":81,"finding":183,"url":184},"Primary Results from Phase 3 EVOKE-03\u002FKEYNOTE D46: Sacituzumab Govitecan + Pembrolizumab in PD-L1 TPS ≥50% Metastatic NSCLC",{"name":180,"slug":181},"sacituzumab govitecan","sacituzumab-govitecan","Gilead Sciences","Median PFS by BICR was numerically longer in the experimental arm (11.8 months) vs control arm (7.7 months) but did not reach statistical significance (HR, 0.81 [95% CI, 0.66; 1.00]; P=0.0252); median OS was 21.5 and 22.8 months; confirmed ORR was 56.6% and 43.7%, respectively.","https:\u002F\u002Fcattendee.abstractsonline.com\u002Fmeeting\u002F21487\u002FPresentation\u002F5045",{"title":186,"drug":187,"company":154,"phase":146,"disease":81,"finding":189,"url":190},"Clinical Outcomes of the Phase III Lonestar Trial: Local Consolidation Therapy After Nivolumab Plus Ipilimumab in NSCLC",{"name":188,"slug":188},"nivolumab","Median OS was 52.8 months with nivolumab\u002Fipilimumab versus 43.2 months with LCT\u002Fnivolumab\u002Fipilimumab (HR 1.16, 95% CI 0.76-1.77; P=.46); median PFS was 24.4 versus 31.3 months (HR 0.80, 95% CI 0.55-1.16; P=.24).","https:\u002F\u002Fcattendee.abstractsonline.com\u002Fmeeting\u002F21487\u002FPresentation\u002F5047",{"title":192,"drug":193,"company":195,"phase":146,"disease":81,"finding":196,"url":197},"Overall Survival Analysis From HARMONi-2: Ivonescimab vs Pembrolizumab as First-Line Treatment for PD-L1-Positive NSCLC",{"name":194,"slug":194},"ivonescimab","Akeso","Median OS was 30.75 months with ivonescimab versus 22.57 months with pembrolizumab (HR 0.73; 95% CI 0.57-0.95; P=0.009), representing a statistically significant and clinically meaningful survival benefit with ivonescimab.","https:\u002F\u002Fcattendee.abstractsonline.com\u002Fmeeting\u002F21487\u002FPresentation\u002F5135",{"title":199,"drug":200,"company":135,"phase":146,"disease":81,"finding":202,"url":203},"Efficacy and Safety of Adjuvant Selpercatinib in Patients With RET+ NSCLC: China Subpopulation Results From LIBRETTO-432",{"name":201,"slug":201},"selpercatinib","The 2-year EFS rate was 100% for selpercatinib vs 59.5% for placebo in patients with Stage II-IIIA, and 100% for selpercatinib vs 70.8% for placebo in patients with Stage IB-IIIA.","https:\u002F\u002Fcattendee.abstractsonline.com\u002Fmeeting\u002F21487\u002FPresentation\u002F4989",{"title":205,"drug":206,"company":208,"phase":146,"disease":81,"finding":209,"url":210},"Befotertinib vs Icotinib as First-Line Treatment for EGFR-mutated Advanced NSCLC: Final Overall Survival Analysis of the Phase III Study",{"name":207,"slug":207},"befotertinib","Betta Pharmaceuticals","Median DOR was 24.9 months with befotertinib and 12.4 months with icotinib.","https:\u002F\u002Fcattendee.abstractsonline.com\u002Fmeeting\u002F21487\u002FPresentation\u002F3189",{"title":212,"drug":213,"company":215,"phase":146,"disease":81,"finding":216,"url":217},"Long Term Survival and Safety Analysis of Exalt3 Study: Ensartinib vs Crizotinib as First Line Regimen in ALK+ NSCLC Patients",{"name":214,"slug":214},"ensartinib","Xcovery Holdings","The 12-month time to treatment failure (TTF) in the brain rate was 4% vs 25% respectively (HR=0.34).","https:\u002F\u002Fcattendee.abstractsonline.com\u002Fmeeting\u002F21487\u002FPresentation\u002F3132",{"title":219,"drug":220,"company":222,"phase":146,"disease":81,"finding":223,"url":224},"First-line Amivantamab-chemotherapy vs Chemotherapy in NSCLC with EGFR Exon 20 Insertions: Overall Survival from PAPILLON",{"name":221,"slug":221},"amivantamab","Johnson & Johnson","Amivantamab-chemotherapy numerically extended the median OS by over 6 months, with a 13% reduction in the risk of death (HR, 0.87; 95% CI, 0.66-1.14; P =0.307).","https:\u002F\u002Fcattendee.abstractsonline.com\u002Fmeeting\u002F21487\u002FPresentation\u002F5034",{"summary":226,"bullets":228},[227],"Small molecules were the most frequent modality (54% of drug-linked abstracts). PDCD1 was the most frequent target (23%). Non-small cell lung cancer (NSCLC) was the most frequent disease (70%).",[229,230,231,232,233],"AstraZeneca had the largest company share (17% of drug-linked abstracts).","Antibody-drug conjugates accounted for 7% of drug-linked abstracts.","Bispecific antibodies accounted for 10% of drug-linked abstracts.","Monoclonal antibodies were the next most frequent modality (38%).","EGFR was the next most frequent target (21%).",[235],{"year":236,"abstracts":237},2025,1744,[239,240],{"name":68,"count":69,"share":70,"previous_count":154,"previous_share":154,"direction":154},{"name":64,"count":65,"share":66,"previous_count":154,"previous_share":154,"direction":154},1793970603094]